Literature DB >> 18222728

Rho exchange factors in the cardiovascular system.

Gervaise Loirand1, Elizabeth Scalbert, Antoine Bril, Pierre Pacaud.   

Abstract

Increasing evidence has accumulated to implicate overactivation of Rho protein as a common component for the pathogenesis of several cardiovascular disorders including hypertension, coronary and cerebral vasospasm, atherosclerosis, and diabetes. Recent advances in Rho protein signaling research indicate that the Rho exchange factors (Rho GEFs) which activate Rho proteins by catalyzing the exchange of GDP for GTP are major regulators of Rho protein activity. In addition, linkage analysis and association studies have recently identified Rho GEFs as susceptibility genes for cardiovascular diseases. All of these data are converging to suggest that as upstream activators of Rho proteins, Rho GEFs expressed in cardiovascular cells are good candidate targets for the treatment of cardiovascular disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18222728     DOI: 10.1016/j.coph.2007.12.006

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  12 in total

1.  Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'-O-Methoxyethyl Antisense Oligonucleotide.

Authors:  Elaine Pirie; Patrick Cauntay; Wuxia Fu; Shayoni Ray; Calvin Pan; Aldonis J Lusis; Jill Hsiao; Sebastien A Burel; Padma Narayanan; Rosanne M Crooke; Richard G Lee
Journal:  Nucleic Acid Ther       Date:  2019-08-01       Impact factor: 5.486

2.  Deciphering the molecular and functional basis of Dbl family proteins: a novel systematic approach toward classification of selective activation of the Rho family proteins.

Authors:  Mamta Jaiswal; Radovan Dvorsky; Mohammad Reza Ahmadian
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

Review 3.  Function and regulation of the Rho guanine nucleotide exchange factor Trio.

Authors:  Susanne Schmidt; Anne Debant
Journal:  Small GTPases       Date:  2014-07-02

4.  Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway.

Authors:  S Chandra; M J Romero; A Shatanawi; A M Alkilany; R B Caldwell; R W Caldwell
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 5.  Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease.

Authors:  Miki Nagase; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2013-01-08       Impact factor: 28.314

6.  Identification of a small GTPase inhibitor using a high-throughput flow cytometry bead-based multiplex assay.

Authors:  Zurab Surviladze; Anna Waller; Yang Wu; Elsa Romero; Bruce S Edwards; Angela Wandinger-Ness; Larry A Sklar
Journal:  J Biomol Screen       Date:  2009-12-11

7.  A structural study of the complex between neuroepithelial cell transforming gene 1 (Net1) and RhoA reveals a potential anticancer drug hot spot.

Authors:  Alain-Pierre Petit; Christel Garcia-Petit; Juan A Bueren-Calabuig; Laurent M Vuillard; Gilles Ferry; Jean A Boutin
Journal:  J Biol Chem       Date:  2018-04-25       Impact factor: 5.157

Review 8.  Arginase in retinopathy.

Authors:  S Priya Narayanan; Modesto Rojas; Jutamas Suwanpradid; Haroldo A Toque; R William Caldwell; Ruth B Caldwell
Journal:  Prog Retin Eye Res       Date:  2013-07-03       Impact factor: 21.198

9.  Effects of MCF2L2, ADIPOQ and SOX2 genetic polymorphisms on the development of nephropathy in type 1 Diabetes Mellitus.

Authors:  Dongying Zhang; Suad Efendic; Kerstin Brismar; Harvest F Gu
Journal:  BMC Med Genet       Date:  2010-07-28       Impact factor: 2.103

10.  Effects of rosuvastatin combined with fasudil therapy on rabbits with dyslipidemia.

Authors:  Zhiming Li; Hua Lian; Qin Liang; Fanfang Zeng; Dongdan Zheng
Journal:  Lipids Health Dis       Date:  2015-05-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.